Human Volunteers Clinical Trial
Official title:
Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance
A recent study by Plenge et al. revealed that rhEpo treatment enhances skeletal muscle
mitochondrial respiratory capacity in humans indicating a muscle ergogenic effect of rhEpo
on aerobic metabolism. The main purpose of the present study is to determine if a shorter
treatment period with micro-dose as well as low-dose rhEpo has similar effects on muscle
mitochondrial function.
Higher doses of rhEpo is known to increase cognitive performance, but it is not clear if
lower doses of rhEpo have similar effects. A second purpose of the present study is to
determine if micro-dose as well as low-dose rhEpo increases cognitive performance.
Twenty-five healthy young male volunteers are randomized to either a low-dose rhEpo (60
IU/kg/week), micro-dose rhEpo (20 IU/kg/week), or placebo control (saline) group. All
subjects receive two subcutaneous injections per week for four weeks. Muscle biopsies are
taken at the beginning and end of the study period. Mitochondrial function is measured in
permeabilized fibres using high-resolution respirometry with the substrates malate (2mM),
octanoyl carnitine (1.5mM), glutamate (10mM), succinate (10mM), under saturating [ADP]
(5mM), and with the membrane uncoupler FCCP (1μM).
On the first day before administration of rhEpo and after the four weeks' treatment the
subjects are undergoing two cognitive performance-tests, Raven Standard Progressive Matrices
(Raven), and Number Finder (NUFI). Weekly semi-structured interviews are conducted by a
blinded interviewer focusing on experienced change in cognitive performance.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00526968 -
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
|
Phase 1 | |
| Completed |
NCT03277456 -
A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1
|
Early Phase 1 | |
| Completed |
NCT02922933 -
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01452425 -
In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome
|
Phase 1 | |
| Completed |
NCT01468714 -
A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01464385 -
Nutrition Beverage Tolerance Study
|
Phase 2 | |
| Completed |
NCT02922946 -
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
|
Phase 1 | |
| Completed |
NCT00254449 -
Effect of NGX-4010 on ENFD and Sensory Function
|
Phase 1 | |
| Completed |
NCT01618877 -
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01618903 -
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
|
Phase 1 | |
| Completed |
NCT00752466 -
A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately
|
Phase 1 | |
| Completed |
NCT00166933 -
Minimal Erythema Dose of UV-B in Normal Population of Taiwan
|
N/A | |
| Completed |
NCT05519514 -
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects
|
Phase 1 | |
| Completed |
NCT01776437 -
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
|
Phase 1 | |
| Completed |
NCT01437033 -
Breath Test for Chemicals (Volatile Organic Compounds)
|
||
| Completed |
NCT01445860 -
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00744809 -
TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.
|
Phase 1 | |
| Unknown status |
NCT00743977 -
Bioequivalence of Phenazopyridine HCl in Healthy Volunteers
|
N/A |